ContraFect (CFRX) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CFRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineRegenETP, Inc. (RGTPQ)finance.yahoo.com - April 16 at 6:57 PMContraFect Corp CFRXQmorningstar.com - January 9 at 3:45 PMContraFect Corp CFRXmorningstar.com - November 19 at 7:11 PMContraFect: Q3 Earnings Snapshotwashingtonpost.com - November 14 at 8:53 PMWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarketbenzinga.com - October 23 at 7:55 AMWhy Is ContraFect (CFRX) Stock Up 23% Today?msn.com - October 16 at 8:41 AMContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Studyfinance.yahoo.com - October 16 at 8:41 AMWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarketbenzinga.com - October 10 at 9:14 AMCFRX: IND Application for CF-370 Submitted to FDA…finance.yahoo.com - September 21 at 6:31 PMAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)markets.businessinsider.com - September 19 at 12:46 PMContraFect to Present at the ASM/ESCMID Joint Conference on Drug Developmentfinance.yahoo.com - September 19 at 12:46 PMContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370finance.yahoo.com - September 18 at 10:37 AMContraFect to Present at the World Anti-Microbial Resistance Congress 2023finance.yahoo.com - August 28 at 9:13 AMCFRX: CF-370 IND to be Filed in 3Q23…finance.yahoo.com - August 17 at 6:29 PMContraFect (CFRX) Receives a Buy from Maxim Groupmarkets.businessinsider.com - August 15 at 7:00 PMContraFect: Q2 Earnings Snapshotsfgate.com - August 14 at 4:09 PMContraFect Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 14 at 4:09 PMContraFect Corpmoney.usnews.com - July 25 at 3:42 PMContraFect (CFRX) Price Target Decreased by 97.37% to 5.10msn.com - July 6 at 11:06 PMContraFect enters a warrant exercise transaction for $9.6Mmsn.com - June 27 at 11:39 AMContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Millionfinance.yahoo.com - June 27 at 11:39 AM8-K: CONTRAFECT Corpmarketwatch.com - June 22 at 2:31 PMCFRX: CF-370 Effective in Rabbit Lung Infection Model Caused by Klebsiella Pneumoniae…finance.yahoo.com - June 22 at 2:31 PMContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogensfinance.yahoo.com - June 20 at 11:11 AMContraFect Gains with Key Data Presentation Set for Next Weekmsn.com - June 9 at 1:39 PMContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023finance.yahoo.com - June 8 at 5:37 PMCFRX: First Patient Dosed in Phase 1b/2 Trial of Exebacase for the Treatment of Chronic Prosthetic Joint Infections…finance.yahoo.com - May 23 at 4:48 PMContraFect Corporation: ContraFect Reports First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 15 at 1:07 PMContraFect Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 8:07 AMWhat's Going On With ContraFecta Stock Todayfinance.yahoo.com - April 27 at 7:26 PMContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Kneefinance.yahoo.com - April 26 at 9:32 AMContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogensfinance.yahoo.com - April 20 at 9:29 AMWhy Is ContraFect (CFRX) Stock Down 14% Today?investorplace.com - April 18 at 11:07 AMmarketbeat.com - April 14 at 12:13 PMMaxim Group upgrades ContraFect (CFRX) to a Buymarkets.businessinsider.com - April 13 at 5:17 PMCFRX: Initiates Phase 1 Trial for Exebacase in Chronic Prosthetic Joint Infection…finance.yahoo.com - April 13 at 12:16 PMIs ContraFect Corp (CFRX) a Bad Choice in Biotechnology Monday?benzinga.com - April 12 at 11:28 PMContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meetingfinance.yahoo.com - April 6 at 1:28 PMContraFect Corporation: ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Updatefinanznachrichten.de - April 1 at 5:38 AMContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Updatefinance.yahoo.com - March 31 at 8:54 AMContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placementfinance.yahoo.com - February 28 at 1:14 PMmarketbeat.com - February 27 at 9:40 AMmarketbeat.com - February 27 at 9:32 AMContraFect (NASDAQ:CFRX) Now Covered by Analysts at StockNews.commarketbeat.com - February 16 at 3:09 AMContraFect Announces Lopsided Interim Results From Pivotal Bacterial Infection Studyfinance.yahoo.com - December 20 at 2:58 PMContraFect Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacasefinance.yahoo.com - December 19 at 5:55 PMContraFect Announces Pricing of $7.0 Million Registered Direct Offering and Concurrent Private Placementfinance.yahoo.com - December 13 at 5:46 PMCFRX: Cleared to Begin Clinical Trial for Exebacase in Chronic Prosthetic Joint Infection…finance.yahoo.com - November 30 at 2:40 PMContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infectionsfinance.yahoo.com - November 28 at 6:20 PMCFRX: Exebacase to be Evaluated as Treatment for Prosthetic Joint Infections…finance.yahoo.com - November 22 at 8:03 PM Get ContraFect News Delivered to You Automatically Sign up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. CFRX Media Mentions By Week CFRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CFRX News Sentiment▼0.000.32▲Average Medical News Sentiment CFRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CFRX Articles This Week▼00▲CFRX Articles Average Week Get ContraFect News Delivered to You Automatically Sign up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALLR News Today ADTX News Today BLPH News Today AMPE News Today APVO News Today SXTC News Today ATHX News Today EVFM News Today EVLO News Today NEPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CFRX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
